ACTIVITY BY QUARTER(variation at current exchange rates)
1stquarter
2ndquarter
in thousands of euros
2016
2017
Var. 17/16
2016
2017
Var. 17/16
France
90,494
97,134
+7.3%
80,469
79,328
-1.4%
Europe (excluding France)
43,685
40,418
-7.5%
31,572
27,421
-13.1%
North America
16,064
18,179
+13.2%
14,113
14,465
+2.5%
Other countries
3,846
4,532
+17.8%
4,061
3,191
-21.4%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
1stquarter
2ndquarter
in thousands of euros
2016
2017
Var. 17/16
2016
2017
Var. 17/16
Non-proprietary Homeopathic Medicines
80,147
81,016
+1.1%
76,001
74,567
-1.9%
OTC Specialties
73,743
78,968
+7.1%
53,719
49,391
-8.1%
Other
199
279
+40.2%
495
447
-9.7%
Group total
154,089
160,263
+4.0%
130,215
124,405
-4.5%
HIGHLIGHTS OF THE SECOND QUARTER 2017
Sales revenue of the second quarter decreased by 4.5% (covering a favorable exchange rate impact of 0.6%) in comparison to the 2016 second quarter. Such decrease was due to a regression of the activity in France and in the other European countries and a progression in North America and Brazil.
Operating income in the first half of 2017 should be lower than the one in 2016.
The implementation of the new organization of the establishments in France has begun in a good climate of consultation with the concerned people and the staff representatives. Six people have refused the proposal to amend their employment contract. The impact on the consolidated half-year financial statements should not be significant.
The acquisition of the land in Les Olmes (area of Lyon) where the future logistic platform of the group shall be located has been concluded on June 10, 2017 for an amount of €2,260 thousand.
In Canada, the Supreme Court rejected the appeal of our Canadian subsidiary against the judgment dated October 26, 2016 of the Quebec Court of Appeal which authorized the start of a class action proceeding. This proceeding continues on the merits before the Superior Court of Quebec. No amount has been accrued to cover this litigation.
Our company carries on the development of homeopathy in the world with the same determination.
Our next update:
September 7, 2017: at market close, publication of 2017 half-year results. Person responsible for financial information: Christian Boiron.
Contact for financial information: Véronique Bouscayrol.
The group's financial information and the glossary are online at: www.boironfinance.com
Boiron SA published this content on 20 July 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 21 July 2017 11:14:03 UTC.
Public permalinkhttp://www.publicnow.com/view/18170A9145CD2E0E4C241E245A5AB8DCEA088A2E
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
